Erratum: Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture (Journal of Neural Transmission (2012) 119 (1467-1476) DOI:10.1007/s00702-012-0816-9);Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture

Journal of Neural Transmission

Volumn 119, Issue 12, 2012, Pages 1467-1476

  Bajic, Natasha ^a   Jenner, Peter ^a   Ballard, Clive G ^a   Francis, Paul T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Lewy body dementia; Neurodegeneration; Neuron; Proteasome; Synaptic proteins

Indexed keywords

BETA III TUBULIN; BETA TUBULIN; DREBRIN; EPOXOMICIN; LACTACYSTIN; PROTEASOME; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN CORTEX; CELL DEATH; ENZYME ACTIVITY; ENZYME INHIBITION; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPSE;

EID: 84878373272     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1046-5     Document Type: Erratum

References (42)

1. Abbott JJ, Howlett DR, Francis PT, Williams RJ (2008) Aβ 1-42 modulation of Akt phosphorylation via α7 nAChR and NMDA receptors. Neurobiol Aging 29:992-1001
2. Bedford L, Hay D, Devoy A, Paine S, Powe DG, Seth R, Gray T, Topham I, Fone K, Rezvani N, Mee M, Soane T, Layfield R, Sheppard PW, Ebendal T, Usoskin D, Lowe J, Mayer RJ (2008) Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 28(33):8189-8198
3. Bingol B, Schuman EM (2004) A proteasome-sensitive connection between PSD-95 and GluR1 endocytosis. Neuropharmacology 47(5):755-763
4. Chen Q, Thorpe J, Keller JN (2005) Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J Biol Chem 280(34):30009-30017
5. Christianson JC, Green WN (2004) Regulation of nicotinic receptor expression by the ubiquitin-proteasome system. EMBO J 23(21):4156-4165
6. Colledge M, Snyder EM, Crozier RA, Soderling JA, Jin Y, Langeberg LK, Lu H, Bear MF, Scott JD (2003) Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron 40(3):595-607
7. Crossthwaite AJ, Hasan S, Williams RJ (2002) Hydrogen peroxide-mediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurons: dependence on Ca(2+) and PI3-kinase. J Neurochem 80(1):24-35
8. Ding Q, Dimayuga E, Markesbery WR, Keller JN (2006) Proteasome inhibition induces reversible impairments in protein synthesis. FASEB J 20(8):1055-1063
9. Drexler HC (1997) Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94(3):855-860
10. Droggiti A, Ho CC, Stefanis L, Dauer WT, Rideout HJ (2011) Targeted disruption of neuronal 19S proteasome subunits induces the formation of ubiquitinated inclusions in the absence of cell death. J Neurochem 119(3):630-643
11. Figueiredo-Pereira ME, Berg KA, Wilk S (1994) A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J Neurochem 63(4):1578-1581
12. Haas KF, Miller SL, Friedman DB, Broadie K (2007) The ubiquitin-proteasome system postsynaptically regulates glutamatergic synaptic function. Mol Cell Neurosci 35(1):64-75
13. Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Naslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L (2000) Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med 6(4):291-302
14. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R (1999) Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem 274(36):25481-25489
15. Jiang X, Litkowski PE, Taylor AA, Lin Y, Snider BJ, Moulder KL (2010) A role for the ubiquitin-proteasome system in activity-dependent presynaptic silencing. J Neurosci 30(5):1798-1809
16. Keyomarsi K, Efuet ET, Bui TN (2011) Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. Cell Biol Toxicol 27(2):123-131
17. Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27(6):1405-1410
18. Laser H, Mack TG, Wagner D, Coleman MP (2003) Proteasome inhibition arrests neurite outgrowth and causes "dying-back" degeneration in primary culture. J Neurosci Res 74(6):906-916
19. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, Jensen PH (2004) Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 279(13):12924-12934
20. Lobner D (2000) Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis? J Neurosci Methods 96(2):147-152
21. Macinnes N, Iravani MM, Perry E, Piggott M, Perry R, Jenner P, Ballard C (2008) Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J Neural Transm 115(6):869-878
22. Martin NP, Lefkowitz RJ, Shenoy SK (2003) Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination. J Biol Chem 278(46):45954-45959
23. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del ST, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65(12):1863-1872
24. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179(1):38-46
25. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O (2002) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 326(3):155-158
26. Pak DT, Sheng M (2003) Targeted protein degradation and synapse remodeling by an inducible protein kinase. Science 302(5649):1368-1373
27. Patrick GN, Bingol B, Weld HA, Schuman EM (2003) Ubiquitin-mediated proteasome activity is required for agonist-induced endocytosis of GluRs. Curr Biol 13(23):2073-2081
28. Payton JE, Perrin RJ, Clayton DF, George JM (2001) Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. Brain Res Mol Brain Res 95(1-2):138-145
29. Perry E, Walker M, Grace J, Perry R (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22(6):273-280
30. Perry EK, Kerwin JM, Perry RH, Irving D, Blessed G, Fairbairn AF (1990) Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type. Dementia 1:2-4
31. Revuelta GJ, Rosso A, Lippa CF (2008) Neuritic pathology as a correlate of synaptic loss in dementia with Lewy bodies. Am J Alzheimers Dis Other Demen 23(1):97-102
32. Rideout HJ, Larsen KE, Sulzer D, Stefanis L (2001) Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 78(4):899-908
33. Rideout HJ, Stefanis L (2002) Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol Cell Neurosci 21(2):223-238
34. Rinetti GV, Schweizer FE (2010) Ubiquitination acutely regulates presynaptic neurotransmitter release in mammalian neurons. J Neurosci 30(9):3157-3166
35. Schulz-Schaeffer WJ (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol (Berl) 120(2):131-143
36. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839-840
37. Sun F, Anantharam V, Zhang D, Latchoumycandane C, Kanthasamy A, Kanthasamy AG (2006) Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 27(5):807-815
38. Tofaris GK, Layfield R, Spillantini MG (2001) Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 509(1):22-26
39. Tsuboi Y, Dickson DW (2005) Dementia with Lewy bodies and Parkinson's disease with dementia: are they different? Parkinsonism Relat Disord 11(Suppl 1):S47-S51
40. Willeumier K, Pulst SM, Schweizer FE (2006) Proteasome inhibition triggers activity-dependent increase in the size of the recycling vesicle pool in cultured hippocampal neurons. J Neurosci 26(44):11333-11341
41. Yew EH, Cheung NS, Choy MS, Qi RZ, Lee AY, Peng ZF, Melendez AJ, Manikandan J, Koay ES, Chiu LL, Ng WL, Whiteman M, Kandiah J, Halliwell B (2005) Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis. J Neurochem 94(4):943-956
42. Zhou RM, Huang YX, Li XL, Chen C, Shi Q, Wang GR, Tian C, Wang ZY, Jing YY, Gao C, Dong XP (2010) Molecular interaction of alpha-synuclein with tubulin influences on the polymerization of microtubule in vitro and structure of microtubule in cells. Mol Biol Rep 37(7):3183-3192